Ozempic in Older AdultsOzempic in older adults — no dose adjustment by age per the label; special considerations: muscle loss, kidney function, polypharmacy, and monitoring.

Short answer: No dose adjustment is needed by age alone — the label notes similar safety and efficacy in patients over 65. But older adults need closer attention to muscle preservation, kidney function, dehydration risk from GI effects, and interactions with other medications.

What the data shows

SUSTAIN and STEP trials included substantial over-65 populations with comparable efficacy and safety. Age alone isn't a reason to avoid — the considerations are practical.

Age-specific considerations

Muscle preservation — weight loss includes lean mass; protein + resistance exercise matter more in older adults (sarcopenia risk)
Dehydration — GI side effects hit harder in older adults; kidney injury risk
Polypharmacy — more medications mean more interaction checks
Kidney function — monitor eGFR; age-related decline common
Fall risk — rapid weight change + dizziness needs attention

Ozempic (semaglutide) FDA Prescribing Information, Novo Nordisk, 2024.

STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding et al., NEJM 2021).

SUSTAIN 6 — Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes (Marso et al., NEJM 2016).

American Diabetes Association — Standards of Care in Diabetes — 2026.

NICE Guideline NG28 — Type 2 diabetes in adults: management.

World Health Organization — Diabetes fact sheet.

Browse all pages